ImageneBio is a San Diego biopharmaceutical company developing IMG-007, an experimental antibody for autoimmune and inflammatory diseases. It last closed at $3.90 on Nov 17, up 21.88% on the day.
Only 1 firm rated IMA in the past 90 days, not enough for a consensus
Average 12-month target
$28.00
▲ 617.9% upside
Based on 1 analyst who set a price target on IMA in the past 90 days. The average target is $28.00, with a high of $28.00 and a low of $28.00, compared with the last close of $3.90.
Low $28.00Avg $28.00High $28.00
Blue marker: last close $3.90
Highest target$28.00
Average target$28.00
Lowest target$28.00
Latest rating changes
HC Wainwright & Co.Initiated
Aug 21Buy$28
Date
Firm
Action
Rating
Price target
Aug 21
HC Wainwright & Co.
Initiated
Buy
$28
Loading…
Technical Analysis
IMA · as of the Nov 17 close · updated after every close
Downtrend
The stock is 1% below its 20 day and 11% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 48). The nearest support is the swing low (Oct 26) at $3.88, and the nearest resistance the 20 day average at $3.93.
Short trendBearish
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 7.6%/day
Key levels
$8.2552 week high+111.5%
$5.44200 day average+39.5%
$4.99100 day average+27.9%
$4.3350 day average+11.0%
$4.30Swing high (Nov 9)+10.3%
$4.24Pivot R1+8.7%
$3.9320 day average+0.8%
$3.90Last close
$3.88Swing low (Oct 26)−0.5%
$3.62Pivot−7.2%
$3.28Pivot S1−15.9%
$3.0052 week low−23.1%
Indicators
RSI (14)
47.75
Middle of its range
Neutral
MACD
-0.22
Below its signal line
Bearish
Stochastic
27.6
Middle of its range
Neutral
ADX (14)
24.5
Weak trend
Williams %R
-30.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-93.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−3.0%
Change over 10 sessions
Bearish
ATR (14)
$0.29
Typical daily range, 7.6% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 16.6%/day
Key levels
$8.2552 week high+111.5%
$5.44200 day average+39.5%
$4.99100 day average+27.9%
$4.3350 day average+11.0%
$4.30Swing high (Nov 9)+10.3%
$4.24Pivot R1+8.7%
$3.9320 day average+0.8%
$3.90Last close
$3.88Swing low (Oct 26)−0.5%
$3.62Pivot−7.2%
$3.28Pivot S1−15.9%
$3.0052 week low−23.1%
Indicators
RSI (14)
34.65
Weak, oversold below 30
Neutral
MACD
-0.60
Below its signal line
Bearish
Stochastic
13.5
Near the bottom of its range
Oversold
ADX (14)
42.5
Strong downtrend
Williams %R
-72.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
-131.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.2%
Change over 10 sessions
Bearish
ATR (14)
$0.65
Typical daily range, 16.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IMA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMA is in one of them and how their past IMA trades turned out.
ImageneBio is a biopharmaceutical company based in San Diego, California, that is developing treatments for immunological, autoimmune and inflammatory diseases. Its main candidate, IMG-007, is an experimental antibody that targets the OX40 receptor on activated T cells. The company is still in clinical trials and is first testing the candidate in atopic dermatitis, a common form of eczema, with plans to study other conditions. Its intended patients are people with these diseases, and its treatments would be prescribed by physicians.